Christopher Aulin

CEO

Christopher has 18 years’ experience working with strategic sales or in management positions in telecom-, IT and med-tech companies.

His previous position was at Abbott where he was Commercial Director and GM,  Abbott Toxicology Nordics.  ​
Prior to Abbott, Christopher was CEO for EDTS that went from om an entrepreneurial company to a fast-growing profitable company that undergone a successful exit by sale.​

Hans Peter Starck-Johnson

Technical Operations Manager & QA/RA

Mr. Starck-Johnson has over 20 years of experience of R&D and product system design. For the last 15 years, focus has been on regulated medical and in vitro device technology at different managing positions, working with the whole chain from conceptualization to manufacturing, most recently as Director of device development at Aerocrine / Circassia, a company with successful sales of medical devices globally. Mr. Starck-Johnson holds several patents and has a MSc degree in Engineering physics from Chalmers University of Technology.

Anna Ohlander

R&D Manager 

Dr. Ohlander has 10 years experience of applied research within the Fraunhofer Gesellschaft, Germanys largest application-oriented research organization. During her time in the Flexible Electronics group at the Fraunhofer EMFT in Munich, she worked on national and international industry oriented research projects and aqcuired a PhD from the KTH Royal Institute of Technology, Sweden. Her research expertise is in integrated foil-based sensors systems, roll-to-roll manufacturing, microfluidics and lab-on-chips.

Peter Bräutigam

Senior Advisor & co-founder

Aishwarya Bindu Suresh

Test Engineer

Peng Zhang

Test Engineer 

John Dinan 

Business Consultant

Christer Wallin 

Business Consultant

Peter Matha

Business Consultant 

Olof Beck

PhD, CSO and co-founder

Before retirement in 2019 Dr. Beck was adjunct Professor at the Karolinska Institute, Sweden and the head of the Pharmacology lab, Karolinska University Hospital. Dr. Beck is a renown scientist in the Bioanalysis field and a pioneer of alternative sampling technologies reaching from human breath sampling to capillary blood sampling. He is the initiator and co-inventor of the Capitainer technology and founder of several start-up companies in alternatic sampling technology. Dr. Beck has published over 300 scientific articles in the pharmacology and toxicology fields.

Mats Bergryd

Business advisor

Mr Bergryd has been active in the health care sector for over 40 years, both in international companies as well as private enterprises. He has been working in several positions in sales, marketing, medical affairs and general management. With his long business experience in fields of pharmaceuticals, medical device technology and medical diagnostics, Mr Bergryd adds key competence to take the Capitainer technology to the market.

Peter Bräutigam

Senior Advisor & co-founder

Mr. Bräutigam has over 40 years’ experience in the diagnostics and blood sampling business with executive positions at Roche Diagnostics, Sarstedt, Syva-Behring-Dade and Becton Dickinson . He is the founder of several companies active in the laboratory medicine area and has served as chairman for the Swedish laboratory technology association. He was the CEO of Capitainer between 2016-2018.

Ernst Westman

Chairman of the Board

Ernst Westman is a civil engineer in chemical engineering with a specialization in medical molecular biology. He has been President and CEO of Boule Diagnostics AB from 1994 to March 31, 2017, where he built and led a world-leading listed company within decentralized blood cell counting to a market capitalization of SEK 1.5 billion. Prior to that, he has had several leading positions within companies’ active in life science and medical diagnostics.

Lars L Gustafsson

Scientific Advisor

Dr Gustafsson is professor in clinical pharmacology at Karolinska Institutet in Stockholm and has worked previously for years as senior consultant in clinical pharmacology with frequent national and international contacts.  His research, teaching and clinical services have been focused on Rational Use of Medicines combining laboratory and clinical approaches in national and international collaboration. He has been scientific and executive leader for numerous projects and is used to develop and implement new diagnostic, drug analytical and IT-based tools for optimal and personalized drug therapy. He has long experience of research and research capacity building in tropical clinical pharmacology using dried blood spot technology for therapeutic drug monitoring. He has supervised 22 PhDs to dissertation and has published 200 original scientific papers.

Ingvar Ryden

Scientific Advisor

Dr Rydén is an Associate Professor in clinical chemistry at Linköping University. He has worked 8 years as the head of a clinical chemistry lab network in South-East of Sweden, and nearly 7 years as senior medical advisor at Roche Diagnostics. He is a co-inventor of novel diagnostic assays and co-founder of startup companies within laboratory diagnostics and life sciences. He has served as a board member in several companies, and has also served as chairman for the Swedish Society of Clinical Chemistry.